Health & Medicine

Statement on the planned hepatitis B birth dose vaccine trial in Guinea-Bissau

29 sec read16 views0 listens

The WHO expresses significant concerns over a proposed hepatitis B birth dose vaccine trial in Guinea-Bissau, citing issues with its scientific justification, ethics, and alignment with human research principles. The trial's design is deemed unethical as it could expose newborns to serious harm by withholding a proven lifesaving intervention. WHO supports Guinea-Bissau in ensuring all newborns receive timely protection against hepatitis B while adhering to the highest ethical standards in research.

Read the full article at WHO News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Cybersecurity9 hours ago28 sec read

AI risk is not just a technology problem: New research shows why leadership matters more than controls

New research from IANS and Artico Search reveals that effective management of AI risks in enterprises depends more on organizational readiness, including leadership understanding and governance structures, rather than just technical security controls...

Ali Nemati

Legal & Policy19 hours ago26 sec read

Morning Docket: 08.28.26

A lawsuit alleges that an AI model was trained on child pornography, and the Defense Department's attempt to ban an AI tool as a national security threat was rejected by a court. These developments highlight ongoing legal and ethical challenges surro...

Ali Nemati

Cybersecurity20 hours ago30 sec read

AI Doesn't Mean the End of Mathematics-at Least Not Yet

Frontier AI models are achieving significant breakthroughs in mathematics, such as disproving conjectures and finding novel applications of known techniques. While these AIs excel at search and recombination, they currently lack the ability to develo...

Ali Nemati